Glial Cell Line-Derived Neurotrophic Factor: GDNF is a peptide in humans that promotes the survival of neurons and is made by the cells that support them. GDNF is especially important in protecting the neurons that produce dopamine and motor neurons. It has been shown to decrease the loss of neurons during development. It might potentially be useful in the treatment or prevention of Parkinson’s disease and amyotrophic lateral sclerosis (ALS). It is also important in regulating kidney and sperm development and has been shown to speed up the clearance of alcohol from the body. Muresanu DF, Ciurea AV, Gorgan RM, Gheorghita E, Florian SI, Stan H, Blaga A, Ianovici N, Iencean SM, Turliuc D, Davidescu HB, Mihalache C, Brehar FM, Mihaescu AS, Mardare DC, Anghelescu A, Chiparus C, Lapadat M, Pruna V, Mohan D, Costea C, Costea D, Palade C, Bucur N, Figueroa J, Alvarez A (2015) A retrospective, multi-center cohort study evaluating the severity- related effects of cerebrolysin treatment on clinical outcomes in traumatic brain injury. CNS Neurol Disord Drug Targets 14(5):587–599. https://doi.org/10.2174/1871527314666150430162531

S. Gauthier, J. Proaño, J. Jia, L. Froelich, J. Vester, and E. Doppler, “Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials.,” Dement Geriatr Cogn Disord, vol. 39, no. 5–6, 2015, doi: 10.1159/000377672. L. Francis-Turner, V. Valouskova (1996) Nerve growth factor and nootropic drug Cerebrolysin but not fibroblast growth factor can reduce spatial memory impairment elicited by fimbria-fornix transection: short-term study https://www.ncbi.nlm.nih.gov/pubmed/8848264 Clinical studies showed that Cerebrolysin is a very safe product and well-tolerated in most patients. No evidence of allergy or anaphylactic reaction has been documented regarding Cerebrolysin. However, minimal side effects can occur which are usually temporary and resolve within 2-3 days. Common side effects include the following: Heiss WD, Brainin M, Bornstein NM et al. (2012) Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke; a journal of cerebral circulation 43, 630-636. Eder et al (2001) Increased density of glutamate receptor subunit 1 due to Cerebrolysin treatment: An immunohistochemical study on aged rats https://www.ncbi.nlm.nih.gov/pubmed/12197668All of the products will be handled only by qualified and properly trained RESEARCH or LABORATORY professionals only. In particular, the combination of Cerebrolysin and motor rehabilitation appears to be especially beneficial following stroke. A phase IV trial, carried out in Korea, found that in patients with severe motor dysfunction, the administration of Cerebrolysin in addition to rehabilitation produced far superior results. These results were confirmed by diffusion tensor and resting state functional MRI[11], [12]. The same benefit was not seen in the setting of mild stroke. This suggests that the major benefit of Cerebrolysin is to stimulate the growth of new neurons and neural connections. In settings where those connections are better persevered (mild stroke), the benefit of Cerebrolysin is not as obvious as in the settings where neurons and their connections are destroyed (severe stroke). Alzheimer’s disease, vascular dementia and Alzheimer-combined vascular genesis: recommended dose is 5ml-30ml. Alcantara-Gonzalez et al (2012) Combined Administration of Cerebrolysin and Donepezil Induces Plastic Changes in Prefrontal Cortex in Aged Mice https://www.ncbi.nlm.nih.gov/pubmed/22826038

Zhang C, Chopp M, Cui Y, Wang L, Zhang R, Zhang L, Lu M, Szalad A, Doppler E, Hitzl M, Zhang ZG (2010) Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke. J Neurosci Res 88(15):3275–3281. https://doi.org/10.1002/jnr.22495 Asghari M, Meshkini A, Salehpoor F, Agazadeh J, Shakeri M, Shokohi G, Ebrahimi N, Bazzazi A, Pourhajshokr N (2014) Investigation of the effect of cerebrolysin on patients with head trauma and diffuse axonal injury. Int J Curr Res Acad Rev 2:62–69 H. S. Sharma, S. Zimmermann-Meinzingen, and C. E. Johanson, “Cerebrolysin reduces blood-cerebrospinal fluid barrier permeability change, brain pathology, and functional deficits following traumatic brain injury in the rat,” Ann. N. Y. Acad. Sci., vol. 1199, pp. 125–137, Jun. 2010, doi: 10.1111/j.1749-6632.2009.05329.x. Plosker GL, Gauthier S (2009) Cerebrolysin: a review of its use in dementia. Drugs Aging 26(11):893–915. https://doi.org/10.2165/11203320-000000000-00000 Alvarez XA, Alvarez I, Martinez A, Romero I, Benito C, Suarez I, Mourente S, Fantini M, Figueroa J, Aleixandre M, Linares C, Muresanu D, Winter S, Moessler H (2020) Serum VEGF predicts clinical improvement induced by Cerebrolysin plus donepezil in patients with advanced Alzheimer’s disease. Int J Neuropsychopharmacol. https://doi.org/10.1093/ijnp/pyaa046

Cerebrolysin has indication-specific dosing. The most common regime for improving brain function is IM injections of 5 ml daily. The course of treatment is 4 weeks unless otherwise prescribed by your attending physician. Wei ZH, He QB, Wang H et al. (2007) Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease. Journal of neural transmission 114, 629-634. Cerebrolysin is a combination of peptides and neurotrophins for enhancing the regeneration of neurons, neural plasticity, and neural protection during neurological illnesses, such as dementia and traumatic brain injuries. It is a neuropeptide drug formed from a series of biochemical and enzymatic reactions on porcine brain proteins. The ultimate product that is formed after a series of reactions has a low molecular weight and increased ability to cross the blood-brain barrier. Muresanu et al (2015) Cerebrolysin and Recovery After Stroke (CARS) A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial https://www.ncbi.nlm.nih.gov/pubmed/26564102 Heiss (2012) Cerebrolysin in Patients With Acute Ischemic Stroke in Asia Results of a Double-Blind, Placebo-Controlled Randomized Trial https://www.ncbi.nlm.nih.gov/pubmed/22282884

P. Y. M. Woo et al., “Randomized, placebo-controlled, double-blind, pilot trial to investigate safety and efficacy of Cerebrolysin in patients with aneurysmal subarachnoid hemorrhage,” BMC Neurol., vol. 20, no. 1, p. 401, Nov. 2020, doi: 10.1186/s12883-020-01908-9. M Brainin (2018) Cerebrolysin: a multi-target drug for recovery after stroke https://pubmed.ncbi.nlm.nih.gov/30004268/Alvarez et al (2008) Reductions in qEEG slowing over 1 year and after treatment with Cerebrolysin in patients with moderate–severe traumatic brain injury https://www.ncbi.nlm.nih.gov/pubmed/18273537 In 2012, a meta-analysis found that Cerebrolysin improves the symptoms of dementia with benefits lasting up to several months after treatment ceased. According to Professor Ricardo Allegri, MD, PhD, it may be useful in improving the neuropsychiatric symptoms associated with dementia[4].

Alvarez XA, Cacabelos R, Sampedro C et al. (2011) Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil. Current Alzheimer research 8, 583-591. Use only sterile, single use syringes (or single use one-way infusion kits). Recommended to use sterile plastic gloves. Vascular dementia is a common form of dementia caused by poor blood flow to the brain. There are currently no proven and licenced treatments for vascular dementia. Cerebrolysin is a medicine that is made from pig's brains and given as an injection. In some countries, Cerebrolysin is used as a treatment for vascular dementia. A previous summary from 2013 considered all studies of Cerebrolysin and vascular dementia. A definitive conclusion as to whether Cerebrolysin was beneficial could not be made.Rare cases of adverse reactions to Cerebrolysin may include fatigue, headaches, dizziness, insomnia, etc. Cerebrolysin was first developed in Austria in 1949. It has since been widely used in the eastern part of the world, particularly Russia and China. It has been considered a Vital and Essential Medicine in Russia since 1992. Within the University, Terry has a number of teaching and supportive roles. including vice chair of ethics committee, advisor of studies for undergraduate medical students and supervising the clinical academic training program. Ruether et al (2001) A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer’s disease https://www.ncbi.nlm.nih.gov/pubmed/11552768 ALL products and services offered are for IN-VITRO RESEARCH purposes ONLY and are NOT TO BE INGESTED or CONSUMED IN ANY MANNER.